RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Perhaps unconsciously, your reference to "mysery" nicely combines the 'misery' and 'mystery' which beshroud the data analysis and its anxious anticipation.

But while waiting to see if the next stirring will be from zephyr or squall, one thought--it doesn't matter when over the next few days RD-2 reports, and when over the next few weeks RD-1 reports. It is what they report that matters, not when that occurs. The timing will make no difference for partnering, or for fundraising, because at most we are talking weeks for RD-1, not months. Even the Europeans--and I say this with some envy of their healthier embrace of time off--have to come back from vacation eventually.

Regarding JerryDylan's comment about Elan/Wyeth's bapineuzumab and the prospects for high impact Ampakines--that's an excellent point. Had Bap's data been strong, it would have heightened the energies going into anti-amyloid strategies, but the questions cropping up about that data have implications for the primacy of the amyloid model in Alzheimer's treatment. That can only be good for non-amyloid alternative approaches to Alzheimer's, of which high-impact Ampakines are one of many.

NeuroInvestment